Kiora Pharmaceuticals Inc. (NASDAQ: KPRX)
$4.36
+0.0650 ( +1.51% ) 19.6K
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Market Data
Open
$4.36
Previous close
$4.29
Volume
19.6K
Market cap
$12.28M
Day range
$4.23 - $4.36
52 week range
$3.60 - $8.98
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | Sep 28, 2023 |
8-k | 8K-related | 13 | Sep 21, 2023 |
8-k | 8K-related | 13 | Sep 01, 2023 |
3 | Insider transactions | 5 | Aug 10, 2023 |
8-k | 8K-related | 13 | Aug 08, 2023 |
10-q | Quarterly Reports | 60 | Aug 08, 2023 |
8-k | 8K-related | 13 | Aug 01, 2023 |
def | Proxies and info statements | 8 | Jul 21, 2023 |
8-k | 8K-related | 12 | Jul 20, 2023 |
pre | Proxies and info statements | 8 | Jul 11, 2023 |